Insurer Transparency Dashboard
Insurers' own published prior-authorization metrics — denial rates, appeal-overturn rates, and decision turnaround times — shown alongside the source for every figure. This is operational transparency, not an attribution of harm to any company.
Compare plans side by side
Each reporting plan's published prior-authorization numbers, color-coded by company. Click a numeric column heading to sort. Every row links to its own source. Verified rows come from payer-hosted disclosures; discovery benchmarks are clearly labeled.
| Plan | Denial rate | Appeal overturn | Mean turnaround | Median turnaround | Type | Source |
|---|---|---|---|---|---|---|
| Loading plan-level data… | ||||||
Loading provenance note…
- Loading data limitations…
The rule behind the numbers
These metrics exist because of a federal transparency rule. Here is what it requires and when.
Loading policy summary…
Transparency, not a body count
Loading explainer…
System-wide picture
Aggregate prior-authorization figures across U.S. insurers, each linked to its published source and badged by provenance.
Loading aggregate metrics…
From a turnaround time to an estimated risk
A plan's published mean or median decision time is an administrative benchmark, not the patient's total treatment delay. The most credible report uses documented clinical dates — order/recommendation, PA submission, denial or appeal, final authorization, and actual treatment start — then applies a peer-reviewed hazard ratio, modeled as HR(days/28)1. If actual dates are not available, the calculator can still show a clearly labeled carrier-turnaround scenario, but it should not be described as documented treatment delay.
Build a documented delay report Read the methodology →
Source: Hanna TP, et al. Mortality due to cancer treatment delay. BMJ 2020;371:m4087. doi:10.1136/bmj.m4087.